J Honing1, J K Smit1, C T Muijs2, J G M Burgerhof3, J W de Groot4, G Paardekooper5, K Muller6, D Woutersen7, M J C Legdeur8, W E Fiets9, A Slot10, J C Beukema2, J Th M Plukker1, G A P Hospers11. 1. Departments of Surgical Oncology. 2. Radiation Oncology. 3. Epidemiology. 4. Departments of Medical Oncology. 5. Radiation Oncology, Isala Klinieken, Zwolle. 6. Department of Radiotherapy, Institute Stedendriehoek en Omstreken, Deventer. 7. Departments of Radiation Oncology. 8. Medical Oncology, Medisch Spectrum Twente, Enschede. 9. Department of Medical Oncology, Medisch Centrum Leeuwarden, Leeuwarden. 10. Department of Radiation Oncology, Radiotherapeutic Institute Friesland, Leeuwarden, The Netherlands. 11. Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen. Electronic address: g.a.p.hospers@umcg.nl.
Abstract
BACKGROUND: In esophageal cancer (EC) patients who are not eligible for surgery, definitive chemoradiation (dCRT) with curative intent using cisplatinum with 5-fluorouracil (5-FU) is the standard chemotherapy regimen. Nowadays carboplatin/paclitaxel is also often used. In this study, we compared survival and toxicity rates between both regimens. PATIENTS AND METHODS: This multicenter study included 102 patients treated in five centers in the Northeast Netherlands from 1996 till 2008. Forty-seven patients received cisplatinum/5-FU (75 mg/m(2) and 1 g/m(2)) and 55 patients carboplatin/paclitaxel (AUC2 and 50 mg/m(2)). RESULTS: Overall survival (OS) was not different between the cisplatinum/5-FU and carboplatin/paclitaxel group {[P = 0.879, hazard ratio (HR) 0.97 [confidence interval (CI) 0.62-1.51]}, with a median survival of 16.1 (CI 11.8-20.5) and 13.8 months (CI 10.8-16.9). Median disease-free survival (DFS) was comparable [P = 0.760, HR 0.93 (CI 0.60-1.45)] between the cisplatinum/5-FU group [11.1 months (CI 6.9-15.3)] and the carboplatin/paclitaxel group [9.7 months (CI 5.1-14.4)]. Groups were comparable except clinical T stage was higher in the carboplatin/paclitaxel group (P = 0.008). High clinical T stage (cT4) was not related to OS and DFS in a univariate analysis (P = 0.250 and P = 0.201). A higher percentage of patients completed the carboplatin/paclitaxel regimen (82% versus 57%, P = 0.010). Hematological and nonhematological toxicity (≥grade 3) in the carboplatin/paclitaxel group (4% and 18%) was significantly lower than in the cisplatinum/5-FU (19% and 38%, P = 0.001). CONCLUSIONS: In this study, we showed comparable outcome, in terms of DFS and OS for carboplatin/paclitaxel compared with cisplatinum/5-FU as dCRT treatment in EC patients. Toxicity rates were lower in the carboplatin/paclitaxel group together with higher treatment compliance. Carboplatin/paclitaxel as an alternative treatment of cisplatinum/5-FU is a good candidate regimen for further evaluation.
BACKGROUND: In esophageal cancer (EC) patients who are not eligible for surgery, definitive chemoradiation (dCRT) with curative intent using cisplatinum with 5-fluorouracil (5-FU) is the standard chemotherapy regimen. Nowadays carboplatin/paclitaxel is also often used. In this study, we compared survival and toxicity rates between both regimens. PATIENTS AND METHODS: This multicenter study included 102 patients treated in five centers in the Northeast Netherlands from 1996 till 2008. Forty-seven patients received cisplatinum/5-FU (75 mg/m(2) and 1 g/m(2)) and 55 patientscarboplatin/paclitaxel (AUC2 and 50 mg/m(2)). RESULTS: Overall survival (OS) was not different between the cisplatinum/5-FU and carboplatin/paclitaxel group {[P = 0.879, hazard ratio (HR) 0.97 [confidence interval (CI) 0.62-1.51]}, with a median survival of 16.1 (CI 11.8-20.5) and 13.8 months (CI 10.8-16.9). Median disease-free survival (DFS) was comparable [P = 0.760, HR 0.93 (CI 0.60-1.45)] between the cisplatinum/5-FU group [11.1 months (CI 6.9-15.3)] and the carboplatin/paclitaxel group [9.7 months (CI 5.1-14.4)]. Groups were comparable except clinical T stage was higher in the carboplatin/paclitaxel group (P = 0.008). High clinical T stage (cT4) was not related to OS and DFS in a univariate analysis (P = 0.250 and P = 0.201). A higher percentage of patients completed the carboplatin/paclitaxel regimen (82% versus 57%, P = 0.010). Hematological and nonhematological toxicity (≥grade 3) in the carboplatin/paclitaxel group (4% and 18%) was significantly lower than in the cisplatinum/5-FU (19% and 38%, P = 0.001). CONCLUSIONS: In this study, we showed comparable outcome, in terms of DFS and OS for carboplatin/paclitaxel compared with cisplatinum/5-FU as dCRT treatment in EC patients. Toxicity rates were lower in the carboplatin/paclitaxel group together with higher treatment compliance. Carboplatin/paclitaxel as an alternative treatment of cisplatinum/5-FU is a good candidate regimen for further evaluation.
Authors: A Herskovic; K Martz; M al-Sarraf; L Leichman; J Brindle; V Vaitkevicius; J Cooper; R Byhardt; L Davis; B Emami Journal: N Engl J Med Date: 1992-06-11 Impact factor: 91.245
Authors: Katrin M Sjoquist; Bryan H Burmeister; B Mark Smithers; John R Zalcberg; R John Simes; Andrew Barbour; Val Gebski Journal: Lancet Oncol Date: 2011-06-16 Impact factor: 41.316
Authors: Ewout F W Courrech Staal; Berthe M P Aleman; Marie-Louise F van Velthuysen; Annemieke Cats; Henk Boot; Edwin P M Jansen; Frits van Coevorden; Johanna W van Sandick Journal: Am J Clin Oncol Date: 2011-08 Impact factor: 2.339
Authors: Lucia M A Crane; Michael Schaapveld; Otto Visser; Marieke W J Louwman; John T M Plukker; Gooitzen M van Dam Journal: Eur J Cancer Date: 2007-05-23 Impact factor: 9.162
Authors: Marco B Polee; Alex Sparreboom; Ferry A L M Eskens; Ronald Hoekstra; Jacqueline van de Schaaf; Jaap Verweij; Gerrit Stoter; Ate van der Gaast Journal: Clin Cancer Res Date: 2004-03-15 Impact factor: 12.531
Authors: Peter S N van Rossum; Nadia Haj Mohammad; Frank P Vleggaar; Richard van Hillegersberg Journal: Nat Rev Gastroenterol Hepatol Date: 2017-12-13 Impact factor: 46.802
Authors: Patrick J McLaren; Anthony P Barnes; Willy Z Terrell; Gina M Vaccaro; Jack Wiedrick; John G Hunter; James P Dolan Journal: Am J Surg Date: 2017-03-27 Impact factor: 2.565
Authors: Mohan Suntharalingam; Kathryn Winter; David Ilson; Adam P Dicker; Lisa Kachnic; André Konski; A Bapsi Chakravarthy; Christopher J Anker; Harish Thakrar; Naomi Horiba; Ajay Dubey; Joel S Greenberger; Adam Raben; Jeffrey Giguere; Kevin Roof; Gregory Videtic; Jondavid Pollock; Howard Safran; Christopher H Crane Journal: JAMA Oncol Date: 2017-11-01 Impact factor: 31.777